Observation Versus Immediate Surgery of Low Risk Bladder Cancer

NCT ID: NCT02700724

Last Updated: 2018-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2018-07-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is a randomized, multi-center, non-inferiority study comparing observation versus immediate surgery for low grade, noninvasive bladder cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observation

Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.

Group Type OTHER

Observation

Intervention Type OTHER

Surveillance Cystoscopy and Urinary Cytology

Intervention Type PROCEDURE

Cytology and cystoscopy are done at the same time

Immediate Surgery

Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.

Group Type OTHER

Immediate Surgery

Intervention Type OTHER

Surveillance Cystoscopy and Urinary Cytology

Intervention Type PROCEDURE

Cytology and cystoscopy are done at the same time

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immediate Surgery

Intervention Type OTHER

Observation

Intervention Type OTHER

Surveillance Cystoscopy and Urinary Cytology

Cytology and cystoscopy are done at the same time

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Transurethral Resection of Bladder Tumor Active Surveillance

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of low grade, noninvasive urothelial carcinoma of the bladder with a new recurrence that meets the following criteria:
* total tumor burden ≤3cm in size (multiple lesions permitted)
* low grade appearance (grade 1 or grade 2)
* noninvasive appearance (Ta)
* no history of carcinoma in situ (CIS) or lesions concerning for CIS
* negative urine cytology (atypical or suspicious for low grade neoplasm are acceptable)

Exclusion Criteria

* High grade and/or invasive and/or carcinoma in situ disease
* Concomitant upper tract urothelial carcinoma
* Any patient who is pregnant or who may have plans to become pregnant.
* Positive cytology
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vanderbilt University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniel Lee

Instructor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel D. Lee, MD

Role: PRINCIPAL_INVESTIGATOR

Vanderbilt University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

151898

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.